Want to see SE:SEZI full AI Analyst Report?
SEZI Stock Chart & Stats
kr5.13
-kr0.14(-2.60%)
At close: 4:00 PM EST
kr5.13
-kr0.14(-2.60%)
Day’s Range― - ―
52-Week Rangekr3.81 - kr7.38
Previous CloseN/A
Volume45.51K
Average Volume (3M)534.13K
Market Cap
kr649.30M
Enterprise Valuekr625.95
Total Cash (Recent Filing)kr55.35M
Total Debt (Recent Filing)kr21.79M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding157,215,040
10 Day Avg. Volume328,516
30 Day Avg. Volume534,125
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr152.70M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthSenzime's consumable-heavy business shows durable structural revenue: strong sensor growth (+40% cc, +27% rolling 12M) and >1M monitored patients indicate an expanding installed base and high attach rates. That recurring consumable demand supports predictable revenue and margin leverage over multi-year hospital procurement cycles.
Improving Underlying Gross MarginsMaterial underlying gross-margin improvement and price increases point to sustainable unit economics if volumes scale. A ~69% underlying margin plus ASP increases create durable gross-margin headroom, helping the company convert incremental sensor sales into operating leverage as the installed base grows and fixed costs are absorbed.
Conservative Capital Structure And RunwayLow leverage combined with cash on hand and an available credit facility provides a tangible runway to execute the operational plan and absorb timing delays. This balance-sheet flexibility reduces near-term refinancing risk and supports management's multi-quarter push to reach cash‑flow positivity if execution on sales and margins holds.
Bears Say
Large And Persistent Cash BurnSenzime's sizable negative operating and free cash flow is a structural vulnerability: continued high cash burn forces reliance on external funding or equity, limits reinvestment, and increases dilution/refinancing risk. Achieving sustained cash‑flow break‑even is essential to preserve capital and support commercialization investments.
Revenue Decline And Deeply Negative ProfitabilityA reversal to negative revenue growth and very large negative EBIT/net margins show the business is not yet operating at sufficient scale. Structural losses reduce return metrics and can erode equity over time, constraining ability to fund growth and slowing the path to sustainable operating profitability absent durable top‑line recovery.
Commercial And Regulatory Timing RisksSenzime's adoption depends on prolonged hospital procurement cycles, KOL support, and regulatory approvals. Delays in U.S. deal closings and timing setbacks in Asian markets create structural unpredictability in revenue recognition and installed‑base expansion, making sustained margin and cash‑flow improvement harder to forecast over coming quarters.
Senzime AB News
SEZI FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was kr3.81 and its highest was kr7.38 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is kr649.30M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Oct 29, 2026 which is in 104 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Jul 16, 2026. The company reported -kr0.136 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -kr0.136 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.496%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in SE:SEZI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Technical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Integrum AB Class B
―
Sedana Medical AB
―
OssDsign AB
―